Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

The rollercoaster ride to anti-cancer antibodies

A recent Keystone meeting highlighted the progress in developing antibody-based therapeutics for cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: IgG antibody—a versatile platform for anti-cancer therapeutics.

References

  1. Köhler, G. & Milstein, C. Nature 256, 495–497 (1975).

    Article  Google Scholar 

  2. Keystone Symposium: Antibody-Based Therapeutics for Cancer, Banff Centre, Banff, Alberta, Canada, February 4–9, 2003.

  3. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Nat. Medicine 6, 443–446 (2000).

    Article  CAS  Google Scholar 

  4. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Proc. Natl. Acad. Sci. USA 95, 652–656 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weiner, L., Carter, P. The rollercoaster ride to anti-cancer antibodies. Nat Biotechnol 21, 510–511 (2003). https://doi.org/10.1038/nbt0503-510

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0503-510

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing